Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

A Multifaceted Approach to Managing Cancer-Related Anxiety and Depression

August 27, 2025
By Boris M. Kiselev, MD
News
Article

Boris M. Kiselev, MD, explores evidence-based interventions for managing cancer-related anxiety and depression.

When addressing the psychological distress that often accompanies a cancer diagnosis, it is crucial for clinicians to consider a comprehensive toolkit that extends beyond conventional psychiatric medications.

While antidepressants and other pharmacological agents have a well-established role and are recommended by clinical guidelines, a truly holistic approach integrates a variety of evidence-based interventions. Boris M. Kiselev, MD, delves into the most effective methods for managing cancer-related anxiety and depression, highlighting the importance of psychotherapy as a foundational and lasting tool. He also discusses the significant benefits of integrative therapies and the critical need to address underlying medical conditions, offering a nuanced perspective on providing compassionate and effective care.

Kiselev is a consult liaison psychiatrist at Atrium Health Carolinas Medical Center, an assistant professor of the Psycho-Oncology Program in the Department of Supportive Oncology at Atrium Health Levine Cancer Institute, and an assistant professor in Internal Medicine.

Transcript:

[Many] times when people think about psycho-oncology, they’re thinking about antidepressants and what other things are out there. The idea that even though antidepressants are helpful and there’s a good evidence base to support their use for anxiety, depression, and cancer, and their use is recommended by guidelines, we still want to make sure we are using all the tools available to us. Psychology guidelines do recommend considering things like mindfulness-based interventions. This includes things like mindfulness-based stress reduction when that’s administered in a group or individual setting that has good, randomized trials supporting efficacy for anxiety and depression in patients dealing with cancer. There’s also good evidence for things like music therapy, relaxation interventions, for moderate quality evidence. There’s also good evidence for exercise being helpful for patients dealing with cancer, and that not only helps with both anxiety and depression, but also with sleep and fatigue. That’s supported by the American College of Sports Medicine Physical Activity Guidelines for adults dealing with cancer.

Additionally, there’s other integrative approaches too. You can consider things like Tai Chi, acupuncture, those all have lower quality evidence, but have been studied. Here at [Levine Cancer Institute], where I work, we have a robust integrative oncology department, and we’re often coordinating with them, referring patients to them, to get them connected with those types of treatment.

Other things to think about when managing these symptoms for patients, especially for those who are working in oncology is to make sure that we’re thinking about their medical comorbidities. For instance, thinking about patients who [receive] immunotherapy, considering endocrinopathies, it could be contributing to their psychiatric symptoms, or thinking about sleep disorders.

In terms of interventions, another thing I want to make sure I talk about as well is psychotherapy, and so the idea is that that’s going to help in many ways when we’re dealing with cancer, to process their experience. Talking about processing grief, learning tools and techniques can help them manage the symptoms day to day, develop coping skills, and help them to get just gain insight into themselves. The great thing about psychotherapy is that even after they complete the psychotherapy treatment that they’re doing, they’ll have those tools that they can take with them afterwards that will continue to be helpful to them in a longitudinal way.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Related Content

Pioneer of Supportive Care Highlights Additional Needs in The Space

Pioneer of Supportive Care Highlights Additional Needs in The Space

Ariana Pelosci
August 27th 2025
Article

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.

START Center Aims to Bring New Cancer Treatments, Trials to The Community

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD
August 27th 2025
Podcast

Perceptions of Dermatologic AEs Could Impact Treatment Adherence

Perceptions of Dermatologic AEs Could Impact Treatment Adherence

Ariana Pelosci
August 27th 2025
Article

Beyond the Tumor: Addressing Body Image in Oncology

Beyond the Tumor: Addressing Body Image in Oncology

Daniel C. McFarland, DO;Michelle Fingeret, PhD
August 27th 2025
Podcast

The EC decision is based on phase 3 DeFi trial results, in which nirogacestat met the primary end point of PFS in patients with progressing desmoid tumors.

Nirogacestat Receives European Approval for Treatment of Desmoid Tumors

Roman Fabbricatore
August 27th 2025
Article

An update of phase 1 data from the CTMX-2051-101 study is expected to be available by the first quarter of 2026.

Safety Review Committee Supports CX-2051 Trial Continuation in Solid Tumors

Roman Fabbricatore
August 27th 2025
Article
Related Content

Pioneer of Supportive Care Highlights Additional Needs in The Space

Pioneer of Supportive Care Highlights Additional Needs in The Space

Ariana Pelosci
August 27th 2025
Article

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, discusses how the START center may expand access to novel therapies for patients who reside in a community.

START Center Aims to Bring New Cancer Treatments, Trials to The Community

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD
August 27th 2025
Podcast

Perceptions of Dermatologic AEs Could Impact Treatment Adherence

Perceptions of Dermatologic AEs Could Impact Treatment Adherence

Ariana Pelosci
August 27th 2025
Article

Beyond the Tumor: Addressing Body Image in Oncology

Beyond the Tumor: Addressing Body Image in Oncology

Daniel C. McFarland, DO;Michelle Fingeret, PhD
August 27th 2025
Podcast

The EC decision is based on phase 3 DeFi trial results, in which nirogacestat met the primary end point of PFS in patients with progressing desmoid tumors.

Nirogacestat Receives European Approval for Treatment of Desmoid Tumors

Roman Fabbricatore
August 27th 2025
Article

An update of phase 1 data from the CTMX-2051-101 study is expected to be available by the first quarter of 2026.

Safety Review Committee Supports CX-2051 Trial Continuation in Solid Tumors

Roman Fabbricatore
August 27th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.